Pertussis, a highly contagious disease of the respiratory tract, is caused by exposure to bacteria (Bordetella pertussis) found in the mouth, nose and throat of an infected person. Pertussis is primarily spread by direct contact with discharge from the nose or throat of infected individuals. Classic - or severe pertussis - as defined by the World Health Organization, consists of at least 21 days of cough illness (with the cough coming in spasms or paroxysms), associated whoops or post-cough vomiting, and laboratory confirmation. Despite widespread vaccination, reports of pertussis continue to rise in the U.S. At particular risk are newborns and babies who have not yet been fully vaccinated against pertussis, who are more likely to have severe pertussis, and who face the possibility of serious complications and death. Over the last decade, 80% of pertussis deaths have occurred in infants under 6 months of age.
A new study from Bangladesh published online in The Pediatric Infectious Disease Journal shows that routinely vaccinating infants against H. influenzae type b (Hib), a bacterium that causes deadly Hib pneumonia and meningitis, could save hundreds of thousands of children in Asia.
GlaxoSmithKline has announced the submission of a regulatory file to European Medicines Agency (EMEA) under Article 58 for the combination vaccine candidate Globorix (diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, Neisseria meningitides serogroups A and C).
Infants with whooping cough were most likely infected by the people they live with, according to a multi-country study led by researchers from the University of North Carolina at Chapel Hill School of Public Health.
The National Vaccine Information Center (NVIC) today released a new analysis of the federal Vaccine Adverse Event Reporting System (VAERS) reports of serious health problems following HPV vaccination (Merck's Gardasil) during the last six months of 2006.
New data from the World Health Organization (WHO) show that the GAVI Alliance, a groundbreaking global initiative to increase access to children's vaccines, has brought immunisation rates to record highs in poor countries.
States that easily permit parents to opt out of vaccinating their children for nonmedical reasons are at increased risk of pertussis (whooping cough), according to a new study from researchers with the Johns Hopkins Bloomberg School of Public Health, the University of Florida and the Centers for Disease Control and Prevention (CDC).
A six-month stockpile of recommended pediatric vaccines would cost $1 billion and could cover more than 90 percent of U.S. children during a six-month interruption in production, say researchers at two Illinois universities.
A red splotch forms where most preschoolers get their fifth, and last, shot of the acellular diphtheria-tetanus-pertussis (DTaP) vaccine, and it can last a few days.
Whooping cough (pertussis) is most easily diagnosed in young children because they develop a characteristic cough - paroxysms of coughing followed by a long inspiration that makes a whooping sound.
In the first study of its kind, researchers at Saint Louis University have demonstrated that immunization with a new vaccine could potentially prevent more than a million cases of pertussis (whooping cough) each year in adolescents and adults.
A vaccine to protect adults and adolescents against illness due to Bordetella pertussis infection--or whooping cough--has proved more than 90 percent effective in a national, large-scale clinical study, according to research results published in this week's issue of The New England Journal of Medicine.
A Cornell University virologist has isolated a highly contagious equine flu virus that is spreading a sometimes-fatal respiratory flu among dogs, and is responsible for a major dog-flu outbreak in New York state. There is no evidence that the virus could infect people.
These results show that a natural product of vitamin A can have an important role in regulating immunity and, when administered along with PIC, might be a potentially powerful nutritional-immunological assist in vaccination."
New research does not support a belief that children receiving multiple vaccines increase their risk of hospitalization for a nontargeted infectious disease, according to a study in the August 10 issue of JAMA: The Journal of the American Medical Association.
According to U.S. health officials, a record high rate of 81 percent of toddlers 19 months to 3 years old are now getting vaccinated with the full recommended series.
The adolescent birth rate has reached another record low, the death rate for children between ages 1 and 4 is the lowest ever, young children are more likely to receive their recommended immunizations, and fourth graders are scoring better in math, according to a yearly compendium of statistics from federal agencies concerned with children.
Parents often wonder why it takes a year or more and multiple shots to fully immunize their children against diseases like diphtheria and pertussis.
The U.S. Food and Drug Administration (FDA) has given drug company Sanofi-Aventis approval to sell Adacel, a vaccine against whooping cough for people ages 11 to 64.
Hoping to prevent ear infections for the more than 15 million children in the United States who suffer from them, a promising new vaccine candidate to prevent middle ear infections (otitis media) is being developed by researchers at the Columbus Children’s Research Institute (CCRI) on the campus of Columbus Children’s Hospital.
Despite childhood vaccination rates at all-time highs, pertussis (whooping cough) has re-emerged over the past two decades, especially among adolescents, adults, and young infants. Because of this resurgence, federal health policymakers are considering a national booster vaccination program.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.